Guggenheim Capital’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-12,787
| Closed | -$249K | – | 1932 |
|
|
2023
Q2 | $249K | Sell |
12,787
-3,880
| -23% | -$92K | ﹤0.01% | 1714 |
|
|
2023
Q1 | $473K | Buy |
16,667
+697
| +4% | +$20.7K | ﹤0.01% | 1511 |
|
|
2022
Q4 | $467K | Buy |
15,970
+225
| +1% | +$7.16K | ﹤0.01% | 1517 |
|
|
2022
Q3 | $416K | Sell |
15,745
-3,910
| -20% | -$143K | ﹤0.01% | 1553 |
|
|
2022
Q2 | $873K | Buy |
19,655
+1,923
| +11% | +$88.3K | 0.01% | 1287 |
|
|
2022
Q1 | $877K | Buy |
17,732
+1,402
| +9% | +$67.3K | 0.01% | 1426 |
|
|
2021
Q4 | $832K | Sell |
16,330
-7,727
| -32% | -$400K | ﹤0.01% | 1453 |
|
|
2021
Q3 | $1.34M | Buy |
24,057
+7,186
| +43% | +$354K | 0.01% | 1268 |
|
|
2021
Q2 | $722K | Buy |
+16,871
| New | +$696K | ﹤0.01% | 1656 |
|
|
2020
Q3 | – | Sell |
-4,319
| Closed | -$207K | – | 1958 |
|
|
2020
Q2 | $207K | Sell |
4,319
-120,144
| -97% | -$5.99M | ﹤0.01% | 1738 |
|
|
2020
Q1 | $5.72M | Sell |
124,463
-703
| -0.6% | -$35.3K | 0.06% | 394 |
|
|
2019
Q4 | $7.52M | Buy |
125,166
+3,420
| +3% | +$204K | 0.06% | 430 |
|
|
2019
Q3 | $6.89M | Sell |
121,746
-622
| -0.5% | -$35K | 0.06% | 448 |
|
|
2019
Q2 | $6.81M | Sell |
122,368
-88
| -0.1% | -$4.59K | 0.06% | 444 |
|
|
2019
Q1 | $6.18M | Sell |
122,456
-2,187
| -2% | -$97.3K | 0.05% | 504 |
|
|
2018
Q4 | $5.02M | Buy |
124,643
+37,174
| +42% | +$1.92M | 0.04% | 565 |
|
|
2018
Q3 | $6.06M | Sell |
87,469
-28,982
| -25% | -$2.2M | 0.04% | 616 |
|
|
2018
Q2 | $8.81M | Sell |
116,451
-74,254
| -39% | -$4.67M | 0.06% | 383 |
|
|
2018
Q1 | $10M | Buy |
190,705
+54,509
| +40% | +$3.17M | 0.02% | 680 |
|
|
2017
Q4 | $7.28M | Sell |
136,196
-5,466
| -4% | -$304K | 0.02% | 823 |
|
|
2017
Q3 | $8.45M | Buy |
141,662
+9,489
| +7% | +$574K | 0.02% | 755 |
|
|
2017
Q2 | $10.4M | Buy |
132,173
+94,290
| +249% | +$7.71M | 0.03% | 656 |
|
|
2017
Q1 | $3.14M | Sell |
37,883
-1,392
| -4% | -$103K | 0.01% | 1315 |
|
|
2016
Q4 | $3.12M | Sell |
39,275
-35,814
| -48% | -$2.6M | 0.01% | 1323 |
|
|
2016
Q3 | $5.26M | Buy |
75,089
+33,234
| +79% | +$1.84M | 0.02% | 990 |
|
|
2016
Q2 | $1.62M | Buy |
41,855
+5,005
| +14% | +$208K | 0.01% | 1704 |
|
|
2016
Q1 | $1.49M | Buy |
36,850
+15,804
| +75% | +$1M | ﹤0.01% | 1782 |
|
|
2015
Q4 | $1.87M | Sell |
21,046
-889
| -4% | -$70.2K | 0.01% | 1665 |
|
|
2015
Q3 | $1.62M | Buy |
+21,935
| New | +$1.82M | 0.01% | 1746 |
|
Other funds holding EGRX
BIP
Guggenheim Capital's EGRX Position: Q3 2023 in Review
Guggenheim Capital sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q3 2023, closing a stake of 12,787 shares — an estimated $249K sold.
Guggenheim Capital first reported a position in EGRX in Q3 2015 and held it in 29 quarters. The position peaked at $10.4M in Q2 2017. 107 funds tracked by Wall St. Rank hold EGRX as of Q3 2023.
- Guggenheim Capital reported no remaining Eagle Pharmaceuticals, Inc. position as of Q3 2023 after selling out during the quarter.
- Guggenheim Capital sold 12,787 Eagle Pharmaceuticals, Inc. shares in Q3 2023, an estimated $249K.
- Guggenheim Capital first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2015 and held it in 29 quarters.
- Guggenheim Capital's Eagle Pharmaceuticals, Inc. position peaked at $10.4M in Q2 2017.
- 107 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q3 2023.
Based on Guggenheim Capital's 13F filing for Q3 2023, filed 14 Nov 2023.